Hanover Advisors’s RxSight RXST Stock Holding History

Hanover Advisors’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,498	Closed	-$223K	–	96
2024 Q4	$223K	Buy	6,498 +1,000	+18%	+$45.1K	0.09%	86
2024 Q3	$272K	Buy	5,498 +500	+10%	+$25.6K	0.11%	75
2024 Q2	$301K	Sell	4,998 -1,000	-17%	-$57.1K	0.13%	74
2024 Q1	$309K	Buy	5,998 +1,000	+20%	+$49.1K	0.13%	73
2023 Q4	$202K	Buy	+4,998	New	+$147K	0.1%	86

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Hanover Advisors's RXST Position: Q1 2025 in Review

Hanover Advisors sold out of RxSight (RXST) in Q1 2025, closing a stake of 6,498 shares — an estimated $223K sold.

Hanover Advisors first reported a position in RXST in Q4 2023 and held it in 5 quarters. The position peaked at $309K in Q1 2024. 192 funds tracked by Wall St. Rank hold RXST as of Q1 2025.

Hanover Advisors reported no remaining RxSight position as of Q1 2025 after selling out during the quarter.
Hanover Advisors sold 6,498 RxSight shares in Q1 2025, an estimated $223K.
Hanover Advisors first reported a position in RxSight in Q4 2023 and held it in 5 quarters.
Hanover Advisors's RxSight position peaked at $309K in Q1 2024.
192 funds tracked by Wall St. Rank held RxSight as of Q1 2025.

Based on Hanover Advisors's 13F filing for Q1 2025, filed 14 May 2025.